| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Thyroid Study Unit, Department of Medicine, University of Chicago, Chicago, IL 60637;
Fujita Health University, Aichi, Japan;
Department of Psychiatry, University of Chicago, Chicago, IL 60637; and
Committee on Immunology, University of Chicago, Chicago, IL 60637
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Several reports indicate that the function of CTLA-4 relates to autoimmunity. Lymphocytes of nonobese diabetic mice, an animal model of autoimmune diabetes, have reduced expression of CTLA-4 (9). CTLA-4-deficient mice show a severe lymphoproliferative disorder, and autoimmune disease, as well as early lethality (10, 11). In theory, reduced expression or function of CTLA-4 may lead to autoimmune T cell clonal proliferation and contribute to the pathogenesis of autoimmune diseases.
Many studies show that specific CTLA-4 gene polymorphisms confer susceptibility to several autoimmune diseases, such as Graves’ disease (GD)3 (12, 13, 14, 15, 16, 17, 18), Hashimoto’s thyroidism (HT) (13, 17, 18, 19), Addison’s Disease (19), insulin-dependent diabetes mellitus (14, 17, 20, 21), rheumatoid arthritis (22), and multiple sclerosis (23). But it is still unclear how CTLA-4 gene polymorphism contributes to the pathogenesis of these diseases.
In this study, we categorized patients with GD, HT, and normal controls (NC) by genotyping a CTLA-4 exon 1 polymorphism. We investigated the function of CTLA-4 in each group and in each genotype using a MLR in the presence or absence of soluble blocking anti-human CTLA-4 Ab. We show that the position 49 G/A alleleism affects the function of the CTLA-4 gene products, appears to augment immune reactivity, and may therefore contribute to the pathogenesis of autoimmune diseases.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Heparinized blood was obtained from 63 autoimmunine thyroid disease patients (43 GD, 18 HT) and from 43 healthy donors (NC). GD was diagnosed on the basis of clinical and laboratory evidence of hyperthyroidism and diffuse goiter, supported by the presence of thyrogrobulin and/or thyroid peroxidase Abs, or exophthalmos. HT was diagnosed by the presence of hypothyroidism, goiter, and thyrogrobulin and/or thyroid peroxidase Abs. PBMCs were separated by Ficoll-Hypaque density gradient centrifugation. Cells were cultured in RPMI 1640 medium containing 10% heat-inactivated FBS, 2-ME (50 µM), and antibiotics. Genomic DNA was obtained from PBMCs using DNAzol (Molecular Research Center, Cincinnati, OH).
Analysis of CTLA-4 gene polymorphism
The CTLA-4 exon 1 position 49 A/G polymorphism was typed using a PCR-restriction fragment length polymorphism method. The appropriate segment of the CTLA-4 gene was amplified using specific primers (5'-GCTCTACTTCCTGAAGACCT-3' and 5'-AGTCTCACTCACCTTTGCAG-3'). PCR was performed using genomic DNA (0.2 µg), Taq polymerase (1 U), 10 pmol of each primer, and dNTPs (200 µM) under the following conditions: initial denaturation for 4 min at 94°C, annealing for 45 s at 57°C, extension for 30 s at 72°C, denaturation for 45 s at 94°C (30 cycles), and a final extension for 10 min at 72°C. The amplified products were digested with restriction enzyme Bbv1 (New England BioLabs, Beverly, MA) and analyzed on 3.5% NuSiev GTG agarose (FMC BioProducts, Rockland, ME) gels.
Proliferation assay
PBMCs (4 x 104 cells/well) plus irradiated EBB (1 x 104 cells/well) as activators were plated in culture medium in 96-well round bottom microplates (Nalge Nunc International, Rochester, NY) and incubated in the presence of soluble anti-human CTLA-4 mAb or isotype control Ig (PharMingen, San Diego, CA) at different concentrations. Cultures were pulsed with 1 µCi/well of [3H]thymidine (ICN, Costa Mesa, CA) after 6 days of incubation at 37°C. Pulsed plates were harvested 16 h later, and [3H]thymidine incorporation was measured in a scintillation counter (LS7500; Beckman, Fullerton, CA). All cultures were performed in triplicate.
Flow cytometric analysis
PBMCs were plated in 96-well round-bottom microplates and incubated at 37°C with or without EBB for different numbers of days. For detection of CTLA-4 on T cells activated with anti-CD3 mAb, PBMCs were cultured for 2 days at 37°C with a 1:10 dilution of supernatant from an anti-human CD3 mAb-producing hybridoma (American Type Culture Collection, Manassas, VA) and human IL-2 (100 U/ml). Following the incubation period, the cells were harvested and resuspended in staining buffer (1% BSA, 0.1% NaN3 in PBS) for detection of surface CTLA-4. For detection of intracellular CTLA-4, the cells were resuspended and fixed in 2% paraformaldehyde, incubated for 30 min at 4°C and then incubated in permeabilization buffer (0.04% saponin, 0.1% OVA, 0.1 M glycine, 0.1% NaN3 in PBS) for 30 min at 4°C. PE-conjugated anti-human CD4 and Cy-Chrome-conjugated anti-human CTLA-4 or similarly labeled isotype control Ig (PharMingen) were added and incubated for an additional 20 min at 4°C. Cells were washed and fixed with 2% paraformaldehyde. Flow cytometry was performed using FACScan (Becton Dickinson, San Jose, CA), and data were analyzed using CellQuest software (Becton Dickinson).
Statistical analysis
Distributions of alleles in patients and controls were compared using Fisher’s exact test. The difference between T cell proliferation in each group was analyzed using Student’s t test. Values of p < 0.05 were regarded as significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
It has been shown previously that CTLA-4 exon 1 gene polymorphism
is associated with GD (14, 15). To determine whether this
correlation existed in our subset of patients, we genotyped NC as well
as individuals with GD and HT. The distribution of the genotypes is
shown in Table I
. Among patients with GD,
there were more individuals with the G/G (17.8% vs 11.6% of controls)
or A/G CTLA-4 exon 1 genotypes (64.4% vs 53.5% control), and
significantly fewer individuals with the A/A alleles (17.8% vs 34.9%
control; p = 0.049) when compared with controls.
Therefore, in accordance with previously published results, the gene
frequency of the G allele was higher in GD patients (50.0%) than in
controls (38.4%) in our population.
|
To be able to analyze CTLA-4 function in the different groups, we
first investigated whether CTLA-4 was expressed in all subgroups and
genotypes of patients following T cell activation. PBMCs from GD, HT,
and NC patients with the different CTLA-4 genotypes were stimulated
with anti-human CD3 mAb and IL-2 for 48 h. Intact and
permeabilized cells were analyzed by flow cytometry for expression of
surface and intracellular CTLA-4, respectively. Unstimulated T cells
expressed undetectable levels of surface or intracellular CTLA-4 (data
not shown). Fig. 1, 1a and
1b show a representative example of surface and
intracellular CTLA-4 expression obtained after anti-CD3 mAb
stimulation. As described previously, intracellular expression of
CTLA-4 was higher than surface expression. The difference in mean
fluorescence intensity (
MFI) between CTLA-4 and isotype control Ig
staining was 6 for surface staining and 84 for intracellular staining.
Using this stimulation protocol, we could not detect any significant
differences in the levels of expression of surface or intracellular
CTLA-4 in T cells from the different subgroups or genotypes of patients
(data not shown).
|
, 2a displays the mean MFI of intracellular CTLA-4
expression over time in two individuals. Levels of expression were much
lower than those following anti-CD3 mAb stimulation, an expected
result because only 10% of T cells are typically alloreactive.
However, CTLA-4 expression was clearly detectable at day 5 after
stimulation. Fig. 1, 2b and 2c show a
representative example of the levels of surface (MFI = 3) and
intracellular (MFI = 8) expression of CTLA-4 5 days after
incubation with irradiated EBB for comparison with levels obtained
after anti-CD3 mAb stimulation. These results indicate that T cells
do express low but detectable levels of CTLA-4 after stimulation
by EBB. Soluble anti-human CTLA-4 mAb augments proliferation of T cells activated with EBB in a dose-dependent manner
Low levels of CTLA-4 expression were induced on T cells in our MLR
system. To determine whether CTLA-4 exerted a function in the MLR, we
attempted to prevent binding of CTLA-4 to its ligands by including a
blocking anti-human CTLA-4 mAb in the culture. Several studies have
shown that soluble anti-CTLA-4 mAbs augment the proliferation of
stimulated T cells, whereas cross-linked anti-CTLA-4 mAbs inhibit T
cell proliferation (8, 24, 25). A dose titration of
soluble anti-CTLA-4 mAb or of control Ig was added at the
initiation of the culture of PBMCs with irradiated EBB. Anti-CTLA-4 mAb
but not control Ig augmented proliferation of T cells stimulated by
irradiated EBB in a dose-dependent manner. Fig. 2 shows the mean + SD of proliferation
data from the whole population of individuals tested. The addition of
250 ng/ml of anti-CTLA-4 induced a highly significant increase in
[3H]thymidine incorporation as compared with
control Ig (p < 0.001). Therefore, blockade of
CTLA-4 binding to B7 family members results in a significant increase
in T cell proliferation, indicating that, despite the low levels of
CTLA-4 expression induced by the MLR conditions, CTLA-4 ligation
reduces T cell responses to allogeneic EBB in this model.
|
We next compared the function of T cells between the different
groups of patients as well as between the different CTLA-4 genotypes.
First, T cell proliferation to EBB in the absence of anti-CTLA-4
mAb was analyzed in patients with GD, HT, and in NC individuals. There
was no significant difference in proliferation between groups (Fig. 3A). This result is similar to
previous reports that used other stimulating conditions
(26, 27, 28). Two possibilities may explain this phenomenon.
This T cell response represents a global response, not specific for the
CTLA-4 pathway or CTLA-4 polymorphism. Presumably, the distribution of
CTLA-4 polymorphisms between subgroups (although statistically
significant) was not enough to differentially affect this global T cell
response.
|
B). This result indicates that the CTLA-4 polymorphism
correlates with differential proliferation of T cells. CTLA-4 polymorphism does affect CTLA-4 function
The expression of the G/G alleles in exon 1 of the CTLA-4 gene
correlated with increased EBB-induced T cell proliferation as compared
with that observed with T cells expressing the A/A alleles. To
determine whether this increase in proliferation was due to a
functional difference exerted by the CTLA-4 proteins, T cell
proliferation between the different genotypic groups was analyzed under
conditions of CTLA-4/B7 blockade by anti-CTLA-4 mAb. Results
obtained with the highest concentration of anti-CTLA-4 mAb (250
ng/ml) previously shown to induce significant augmentation of T cell
proliferation as compared with control Ig (see Fig. 2) were used for
this purpose. We calculated the percentage of augmentation after CTLA-4
blockade using the following formula: % of augmentation = [(T
cell proliferation with anti-CTLA-4 mAb (CPM))/(T cell
proliferation with control Ig (CPM))] x 100 (%). Proliferation of T
cells from patients with GD or HT was augmented less by the addition of
blocking anti-CTLA-4 mAb in the culture than was proliferation of T
cells from NC individuals (GD, HT, NC = 156%, 164%, 175%,
respectively). This result suggests that the inhibitory function of
CTLA-4 is less potent in T cells from patients with GD and HT than from
NC. When the results were analyzed based on the CTLA-4 gene
polymorphism, proliferation of T cells from subjects with the G/G
allele was augmented 132% following CTLA-4 blockade, whereas
proliferation of cells from A/A-expressing subjects was increased 193%
(p = 0.019) (Fig. 4). Furthermore, we compared the
augmentation of T cell proliferation in relation to the polymorphism in
each subgroup (GD, HT, NC). As shown in Fig. 5, a similar tendency occurred not only
in GD patients but also in HT and NC subjects. The difference between
A/A and G/G is significant statistically only in NC, because of the
reduced number of patients in each group. Taken together, these results
point to a role of CTLA-4 gene polymorphism in the function exerted by
the CTLA-4 protein.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We found that the CTLA-4 G/G genotype correlated with reduced function of the CTLA-4 protein in the three populations tested, regardless of the presence of an autoimmune disease. However, the G/G genotype was more frequent in the population with GD and HT than in the NC population. The fact that some NC individuals bearing the G/G genotype do not develop autoimmune diseases whereas some patients with the A/A genotype suffer from autoimmunity underlines the multifactorial etiology of autoimmune diseases. Indeed, in most autoimmune diseases, susceptibility is also linked closely with MHC class II alleles. Presumably this is because T cells recognize the Ag presented by MHC class II on APCs, and this interaction makes the MHC class II region a strong candidate for involvement in T cell-mediated autoimmune diseases (32). For example, insulin-dependent diabetes mellitus is associated with MHC class II DR3 and DR4 (33), GD with DR3 (34), and HT with DR3 and DR4 (35). In addition, thyroid follicular cells, which express MHC class II Ags, are the target for the autoimmune process in GD. Weetman suggested that the autoreactive T cells initially stimulated by conventional APC may be stimulated by class II-positive thyroid follicular cells in the presence of B7 expressing APC and exacerbate disease (36).
CTLA-4 has been shown in multiple in vitro and in vivo systems to inhibit T cell responses. How this inhibitory effect is mediated is still unclear. Because CTLA-4 binds B7 family members with much higher affinity than CD28, expression of CTLA-4 upon T cell stimulation may result in CTLA-4 molecules scavenging B7 ligands away from CD28, therefore reducing the costimulatory effects of CD28. In addition, the cytoplasmic tail of CTLA-4 shares some common binding motifs with CD28, such as a phosphatidylinositol 3-kinase binding domain, suggesting that CTLA-4 activation may lead to sequestering of intracellular enzymes away from the CD28 cytoplasmic tail, resulting in dampening of CD28 signaling. However, CTLA-4 has also been shown to mediate down-regulation of T cell responses in the absence of CD28 (37, 38), indicating that CTLA-4 must have signaling properties independent of its effects on CD28. In particular, CTLA-4 cross-linking has been shown to reduce activation of the mitogen-activated protein kinase pathway induced following TCR stimulation in the absence of a second signal (39).
Our study indicates that the inhibitory effect of CTLA-4 on T cells was less potent in cells from subjects with G/G than A/A alleles. Several hypotheses can explain this result. First, it is possible that a CTLA-4 gene polymorphism in the leader sequence (exon 1) may influence the level or pattern of expression of the protein. Thus, T cells from G/G-expressing patients would be expected to have reduced levels of CTLA-4 following T cell activation as compared with T cells from A/A-expressing patients. Alternatively, the trafficking properties of CTLA-4 may be altered, such that the total level of CTLA-4 may be similar but the levels of CTLA-4 responsible for the negative signaling capacity of the molecule may be reduced. Indeed, CTLA-4 is expressed at much higher levels in intracellular regions than on the surface of activated T cells and gets rapidly endocytosed after reaching the cell surface. The localization from which CTLA-4 exerts its negative effects on T cell responses is unclear, but it is conceivable that differences in the leader sequence of the gene may result in altered rates of endocytosis or surface trafficking. Studies to examine surface and intracellular expression of CTLA-4 as well as rates of endocytosis under our stimulating conditions are under way. However, we have not been able so far to find significant differences in patients or cell-lines expressing the different genotypes (data not shown), although minimal differences may be all that is needed to result in differential CTLA-4 function.
Other hypotheses to explain reduced function of CTLA-4 in cells from G/G-expressing individuals are decreased activation by CTLA-4 ligation of a downstream signaling inhibitory pathway or reduced programmed cell death induced by cross-linking of CTLA-4. However, it is unlikely that a polymorphism in a leader sequence of a gene would result in altered properties mediated by the cytoplasmic tail of the gene product. Moreover, we have compared the percentage of apoptosis induced by different means in T cells from patients expressing the G/G vs the A/A alleles and have not found any significant differences (data not shown).
An association between CTLA-4 gene polymorphism and CTLA-4 protein function has not been reported previously. It was important that the conditions used to stimulate T cells to detect differences in CTLA-4 function were as close to physiological as possible. Indeed, the stimuli used in mouse experiments to stimulate T cells for CTLA-4 expression are often very potent (anti-CD3 plus anti-CD28 mAbs (5) or PMA plus ionomycin (40)). It is possible that under those conditions CTLA-4 expression is maximal and differences in CTLA-4 function may therefore not be detectable if variations in expression depending on genotype are subtle. To be able to compare CTLA-4 function between patients, we felt it was necessary to ligate CTLA-4 with its natural ligand B7 rather than with cross-linking Abs. In addition, a system in which the stimulus is always the same would ensure reduced variability. To this end, we used irradiated EBB that express allogeneic MHC class II and B7-1 to ligate TCR and CTLA-4, respectively. The proliferative response was largely the result of CD4 T cell recognition of MHC class II gene products.
Under suboptimal activation conditions, CTLA-4 might serve to attenuate weak signals mediated by the TCR and CD28 (41). Recently, Brunner et al. showed that cross-linked anti-CTLA-4 mAb suppressed IL-2 mRNA accumulation at 4 h after activation, a time at which CTLA-4 was undetectable on the cell surface, and suppressed T cell proliferation (42). We described how T cells activated by EBB showed submaximal expression of CTLA-4 compared with the response using anti-CD3. We used soluble anti-CTLA-4 mAb to block the negative signal between B7 and CTLA-4 and showed suppression of T cell activation via the CTLA-4 pathway. These observations suggest that CTLA-4 is induced at sufficient levels to regulate T cell responses.
We cannot exclude the effect of other cells, such as monocytes and B cells present in our system, on cytokine production or T cell proliferation. This possibility can be eliminated by studies using purified T cells, T cell lines, or CTLA-4-transfected T cells, which are in progress. However, the lower suppression associated with the G/G allele is seen in all subgroups (GD, HT, and NC) indicating that the concept is applicable in general to immune responses and is not specific for the cell types present in patients with GD or HT.
GD is an autoimmune disease and is thought to be caused by multiple genetic factors. CTLA-4 gene polymorphism is one of these factors. CTLA-4 encoded by the G/G alleles appears to cause less suppression of T cells perhaps allowing expansion of autoimmune clones. This reduced CTLA-4 function may also explain the relation of the CTLA-4 polymorphism to several other autoimmune illnesses.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Leslie J. DeGroot, Thyroid Study Unit/Mail Code 3090, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637-1470.
3 Abbreviations used in this paper: GD, Graves’ disease; HT, Hashimoto’s thyroidism; NC, normal controls; MFI, mean fluorescence intensity
Received for publication May 30, 2000. Accepted for publication August 24, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155:1544.[Abstract]
and ZAP70. J. Exp. Med. 186:1645.This article has been cited by other articles:
|
|
 |
|
  A. K. Steck, W. Zhang, T. L. Bugawan, K. J. Barriga, A. Blair, H. A. Erlich, G. S. Eisenbarth, J. M. Norris, and M. J. Rewers Do Non-HLA Genes Influence Development of Persistent Islet Autoimmunity and Type 1 Diabetes in Children With High-Risk HLA-DR,DQ Genotypes? Diabetes, April 1, 2009; 58(4): 1028 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Huber, F. Menconi, S. Corathers, E. M. Jacobson, and Y. Tomer Joint Genetic Susceptibility to Type 1 Diabetes and Autoimmune Thyroiditis: from Epidemiology to Mechanisms Endocr. Rev., October 1, 2008; 29(6): 697 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sun, Y. Zhou, M. Yang, Z. Hu, W. Tan, X. Han, Y. Shi, J. Yao, Y. Guo, D. Yu, et al. Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer Cancer Res., September 1, 2008; 68(17): 7025 - 7034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Stohl, N. Jacob, W. J. Quinn III, M. P. Cancro, H. Gao, C. Putterman, X. Gao, L. Pricop, and M. N. Koss Global T Cell Dysregulation in Non-Autoimmune-Prone Mice Promotes Rapid Development of BAFF-Independent, Systemic Lupus Erythematosus-Like Autoimmunity J. Immunol., July 1, 2008; 181(1): 833 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hayashi, T. Kouki, N. Takasu, S. Sunagawa, and I. Komiya Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients. Eur. J. Endocrinol., June 1, 2008; 158(6): 817 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Tsukahara, T Iwamoto, K Ikari, E Inoue, T Tomatsu, M Hara, H Yamanaka, N Kamatani, and S Momohara CTLA-4 CT60 polymorphism is not an independent genetic risk marker of rheumatoid arthritis in a Japanese population Ann Rheum Dis, March 1, 2008; 67(3): 428 - 429. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Azarian, M. Busson, V. Lepage, D. Charron, A. Toubert, P. Loiseau, R. P. de Latour, V. Rocha, and G. Socie Donor CTLA-4 +49 A/G*GG genotype is associated with chronic GVHD after HLA-identical haematopoietic stem-cell transplantations Blood, December 15, 2007; 110(13): 4623 - 4624. [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Chang, Y.-T. Chang, Y.-W. Tien, P.-C. Liang, I-S. Jan, S.-C. Wei, and J.-M. Wong T-Cell Regulatory Gene CTLA-4 Polymorphism/Haplotype Association with Autoimmune Pancreatitis Clin. Chem., September 1, 2007; 53(9): 1700 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K. Kavvoura, T. Akamizu, T. Awata, Y. Ban, D. A. Chistiakov, I. Frydecka, A. Ghaderi, S. C. Gough, Y. Hiromatsu, R. Ploski, et al. Cytotoxic T-Lymphocyte Associated Antigen 4 Gene Polymorphisms and Autoimmune Thyroid Disease: A Meta-Analysis J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3162 - 3170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Perez-Garcia, R. De la Camara, J. Roman-Gomez, A. Jimenez-Velasco, M. Encuentra, J. B. Nieto, J. de la Rubia, A. Urbano-Ispizua, S. Brunet, A. Iriondo, et al. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood, July 1, 2007; 110(1): 461 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-H. Su, T.-Y. Chang, Y.-J. Lee, C.-K. Chen, H.-F. Liu, C.-C. Chu, M. Lin, P.-T. Wang, W.-C. Huang, T.-C. Chen, et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women Carcinogenesis, June 1, 2007; 28(6): 1237 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.S. C. Graham, A.K. Wong, N.J. McHugh, J.C. Whittaker, and T. J. Vyse Evidence for unique association signals in SLE at the CD28-CTLA4-ICOS locus in a family-based study Hum. Mol. Genet., November 1, 2006; 15(21): 3195 - 3205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-Y. Cheng, J.-T. Lin, L.-T. Chen, C.-T. Shun, H.-P. Wang, M.-T. Lin, T.-E. Wang, A.-L. Cheng, and M.-S. Wu Association of T-Cell Regulatory Gene Polymorphisms With Susceptibility to Gastric Mucosa-Associated Lymphoid Tissue Lymphoma J. Clin. Oncol., July 20, 2006; 24(21): 3483 - 3489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Tapirdamaz, V Pravica, H J Metselaar, B Hansen, L Moons, J B J van Meurs, I V Hutchinson, J Shaw, K Agarwal, D H Adams, et al. Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation Gut, June 1, 2006; 55(6): 863 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Barker Type 1 Diabetes-Associated Autoimmunity: Natural History, Genetic Associations, and Screening J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1210 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K. Kavvoura and J. P. A. Ioannidis CTLA-4 Gene Polymorphisms and Susceptibility to Type 1 Diabetes Mellitus: A HuGE Review and Meta-Analysis Am. J. Epidemiol., July 1, 2005; 162(1): 3 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Weng, M.-J. Wu, and W.-S. Lin CT60 Single Nucleotide Polymorphism of the CTLA-4 Gene Is Associated with Susceptibility to Graves' Disease in the Taiwanese Population Ann. Clin. Lab. Sci., January 1, 2005; 35(3): 259 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hiromatsu, T. Fukutani, M. Ichimura, T. Mukai, H. Kaku, H. Nakayama, I. Miyake, S. Shoji, Y. Koda, and T. Bednarczuk Interleukin-13 Gene Polymorphisms Confer the Susceptibility of Japanese Populations to Graves' Disease J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 296 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Anjos, M.-C. Tessier, and C. Polychronakos Association of the Cytotoxic T Lymphocyte-Associated Antigen 4 Gene with Type 1 Diabetes: Evidence for Independent Effects of Two Polymorphisms on the Same Haplotype Block J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6257 - 6265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Hwang, W. B. Sweatt, M. Mashayekhi, D. A. Palucki, H. Sattar, E. Chuang, and M.-L. Alegre Transgenic Expression of CTLA-4 Controls Lymphoproliferation in IL-2-Deficient Mice J. Immunol., November 1, 2004; 173(9): 5415 - 5424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Thio, T. L. Mosbruger, R. A. Kaslow, C. L. Karp, S. A. Strathdee, D. Vlahov, S. J. O'Brien, J. Astemborski, and D. L. Thomas Cytotoxic T-Lymphocyte Antigen 4 Gene and Recovery from Hepatitis B Virus Infection J. Virol., October 15, 2004; 78(20): 11258 - 11262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Prud'homme Altering immune tolerance therapeutically: the power of negative thinking J. Leukoc. Biol., April 1, 2004; 75(4): 586 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-W. Wang, R.-T. Liu, S.-H. H. Juo, S.-T. Wang, Y.-H. Hu, C.-J. Hsieh, M.-H. Chen, I-Y. Chen, and C.-L. Wu Cytotoxic T Lymphocyte-Associated Molecule-4 Polymorphism and Relapse of Graves' Hyperthyroidism after Antithyroid Withdrawal J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 169 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Prabhakar, R. S. Bahn, and T. J. Smith Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy Endocr. Rev., December 1, 2003; 24(6): 802 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Keler, E. Halk, L. Vitale, T. O'Neill, D. Blanset, S. Lee, M. Srinivasan, R. F. Graziano, T. Davis, N. Lonberg, et al. Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques J. Immunol., December 1, 2003; 171(11): 6251 - 6259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tomer and T. F. Davies Searching for the Autoimmune Thyroid Disease Susceptibility Genes: From Gene Mapping to Gene Function Endocr. Rev., October 1, 2003; 24(5): 694 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Jin, W. Teng, S. Ben, X. Xiong, J. Zhang, S. Xu, Y. Y. Shugart, L. Jin, J. Chen, and W. Huang Genome-Wide Scan of Graves' Disease: Evidence for Linkage on Chromosome 5q31 in Chinese Han Pedigrees J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1798 - 1803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Vaidya, P. Kendall-Taylor, and S. H. S. Pearce The Genetics of Autoimmune Thyroid Disease J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5385 - 5397. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Anjos, A. Nguyen, H. Ounissi-Benkalha, M.-C. Tessier, and C. Polychronakos A Common Autoimmunity Predisposing Signal Peptide Variant of the Cytotoxic T-lymphocyte Antigen 4 Results in Inefficient Glycosylation of the Susceptibility Allele J. Biol. Chem., November 22, 2002; 277(48): 46478 - 46486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Shah, K. Banks, A. Patel, S. Dogra, R. Terrell, P. A. Powers, C. Fenton, C. A. Dinauer, R. M. Tuttle, and G. L. Francis Intense Expression of the B7-2 Antigen Presentation Coactivator Is an Unfavorable Prognostic Indicator for Differentiated Thyroid Carcinoma of Children and Adolescents J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4391 - 4397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M-F Liu, C-R Wang, L-C Lin, and C-R Wu CTLA-4 gene polymorphism in promoter and exon-1 regions in Chinese patients with systemic lupus erythematosus Lupus, September 1, 2001; 10(9): 647 - 649. [Abstract] [PDF]
|
|
|
|
|
|
P. M. Holopainen and J. A. Partanen Technical Note: Linkage Disequilibrium and Disease-Associated CTLA4 Gene Polymorphisms J. Immunol., September 1, 2001; 167(5): 2457 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Davidson and B. Diamond Autoimmune Diseases N. Engl. J. Med., August 2, 2001; 345(5): 340 - 350. [Full Text] [PDF]
|
|
|
|
|
|
Y. Tomer, D. A. Greenberg, G. Barbesino, E. Concepcion, and T. F. Davies CTLA-4 and Not CD28 Is a Susceptibility Gene for Thyroid Autoantibody Production J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1687 - 1693. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
